; (H) with respect to each servicemember identified in subparagraph (G), whether the servicemember was referred after a positive drug test and the source of such referral; (I) of the servicemembers identified in subparagraph (G), the number of servicemembers who engaged in such medical treatment; (J) the number of servicemembers who suffered a fatal overdose in which a bystander was present; and (K) the number of fatal overdoses. (3) The total number of servicemembers who suffered a non-fatal overdose during the previous calendar year, including— (A) demographic information, including gender, race, age, military department, military rank, pay grade, station, number of previous deployments, and whether such member was a victim of military sexual assault; (B) a list of the substances involved in the non-fatal overdose; and (C) a determination of whether the non-fatal overdose was intentional. (4) Of the servicemembers identified in paragraph (3)— (A) the number of servicemembers who previously had a non-fatal overdose; (B) the number of servicemembers who received mental health or substance use disorder services prior to a non-fatal overdose; (C) the number of servicemembers with co-morbid mental health diagnoses prior to a non-fatal overdose; (D) the number of servicemembers who had been prescribed opioids, benzodiazepines, or stimulants prior to a non-fatal overdose; (E) the number of servicemembers who had a positive drug test prior to the non-fatal overdose, including any substance identified in such test; (F) the number of servicemembers who suffered a non-fatal overdose in which a bystander was present; (G) the number of servicemembers who had been categorized as high risk and prescribed or provided naloxone prior to a non-fatal overdose; (H) the number of servicemembers who suffered a non-fatal overdose in which naloxone was administered; (I) the number of servicemembers referred to medical treatment, including medication treatment for opioid use disorder, following a non-fatal overdose